Name: | torsemide |
---|---|
PubChem Compound ID: | 41781 |
Molecular formula: | C16H20N4O3S |
Molecular weight: | 348.421 g/mol |
Synonyms: |
KBio2_007392; Unat; CAS-56211-40-6; CCRIS 6736; GJ-1090; Luprac (TN); Torasemidum [INN-Latin]; KBio2_002256; Luprac; Torasemida [INN-Spanish].
show more » |
Name: | torsemide |
---|---|
Name (isomeric): | DB00214 |
Drug Type: | small molecule |
Synonyms: |
Torasemidum [INN-Latin]; Torasemida [INN-Spanish]; Torsemide
|
Brand: | Demadex, Luprac |
Category: | Diuretics, Antihypertensive Agents |
CAS number: | 56211-40-6 |
Indication: | For the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents. |
---|---|
Pharmacology: |
Torasemide (INN) or torsemide (USAN) is a novel loop diuretic belonging to pridine sulphonyl urea. It differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Like thiazides, loop diuretics must be secreted into the tubular fluid by proximal tubule cells. In the thick ascending loop Na+ and Cl- reabsorp...
show more » |
Mechanism of Action: |
Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to...
show more » |
Absorption: | Rapidly absorbed following oral administration. Absolute bioavailability is 80%. Food has no effect on absorption. |
Protein binding: | > 99% |
Biotransformation: | Metabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively. |
Route of elimination: | Torsemide is cleared from the circulation by both hepatic metabolism (approximately 80% of total clearance) and excretion into the urine (approximately 20% of total clearance in patients with normal renal function). |
Half Life: | 3.5 hours |
Toxicity: | Symptoms of overdose include dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Oral LD50 in rat is 5 g/kg, and intravenous LD50 in rat is 500 mg/kg. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|